Migraines

Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter, prospective, randomized, singleblinded, Controlled investigational study using its neurostimulation system to stimulate the occipital nerves as a potential approach to treating medically refractory chronic migraines will be presented during a late-breaking session at the annual scientific meeting of the American Headache Society (AHS) tomorrow in Boston.

More: continued here